BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
May 24, 2024 08:00 ET
|
BriaCell Therapeutics Corp.
83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression free survival (PFS) of 4.1 months in ADC...
Life Science Technical Accounting CPE Update (2-Day Virtual Conference: September 17-18, 2024) - Understand the Latest Accounting Changes in Key Areas
May 24, 2024 07:32 ET
|
Research and Markets
Dublin, May 24, 2024 (GLOBE NEWSWIRE) -- The "Life Science Technical Accounting CPE Update 2024" conference has been added to ResearchAndMarkets.com's offering. This conference will cover the...
2-Day Online Process Validation Guidance Requirements Course: July 25-26, 2024 (FDA and EU Annex 15: Qualifications and Validation)
May 24, 2024 07:28 ET
|
Research and Markets
Dublin, May 24, 2024 (GLOBE NEWSWIRE) -- The "Process Validation Guidance Requirements course (FDA and EU Annex 15: Qualifications and Validation) Course" training has been added to ...
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
May 24, 2024 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, May 24, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop...
Global Next Generation Sequencing Sample Preparation Market Analysis & Forecast 2024-2034: The Surge of Next Generation Sequencing in Diagnostics and Drug Discovery
May 24, 2024 06:06 ET
|
Research and Markets
Dublin, May 24, 2024 (GLOBE NEWSWIRE) -- The "Global Next Generation Sequencing Sample Preparation Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's...
Single Domain Antibody Platforms MarketResearch 2024-2031: Strategic Collaborations Driving Expansion, Focus on Pioneering Cancer Treatments, US Leads Innovations
May 24, 2024 04:28 ET
|
Research and Markets
Dublin, May 24, 2024 (GLOBE NEWSWIRE) -- The "Single Domain Antibody Platforms Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade,...
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
May 23, 2024 21:03 ET
|
Adlai Nortye Ltd.
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology...
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
May 23, 2024 17:30 ET
|
Elicio Therapeutics, Inc.
ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levelsELI-002 7P generated an mKRAS-specific T...
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
May 23, 2024 17:05 ET
|
Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
May 23, 2024 17:05 ET
|
Affimed N.V.
In 15 response-evaluable patients with metastatic EGFR wild-type NSCLC, who were pretreated with platinum doublet chemotherapy and checkpoint inhibitors, the combination of AFM24 and atezolizumab led...